|
Plerixafor This page contains brief information about plerixafor and a collection of links to more information about the use of this drug and ongoing clinical trials. | US Brand Name(s): |  | Mozobil | | | | FDA Approved: | | Yes |
Plerixafor is approved by the Food and Drug Administration (FDA) to be given together with granulocyte-colony stimulating factor (G-CSF) to patients with non-Hodgkin lymphoma (NHL) or multiple myeloma. Plerixafor and G-CSF help move stem cells from the bone marrow to the bloodstream so they can be collected, stored, and then given back to the patient in autologous stem cell transplantation. Plerixafor is also being studied in the treatment of other types of cancer.
Information from the FDA
FDA Approval for Plerixafor - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Clinical TrialsClinical Trials for Plerixafor - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |
